| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
173,744,000 |
| Market
Cap: |
1.41(B) |
| Last
Volume: |
148,509 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.6 - $15.45 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.3 |
| Insider 6 Months : 8.3 |
| Insider 3/6 Months : 16.7 |
|
| Guru Rank Number : 607 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focusing on developing the treatment of GI diseases. LINZESS® (linaclotide), Co.'s commercial product, is a product in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is available to adult men and women suffering from IBS-C or CIC in the U.S. and Mexico and to adult men and women suffering from IBS-C in Japan and China. Co. has partnerships with pharmaceutical companies to support the development and commercialization of linaclotide.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
17,604 |
17,604 |
53,676 |
53,676 |
| Total Buy Value |
$160,420 |
$160,420 |
$460,539 |
$460,539 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
3 |
3 |
| Total Shares Sold |
280,916 |
294,129 |
403,559 |
1,047,483 |
| Total Sell Value |
$4,281,159 |
$4,424,082 |
$5,556,813 |
$12,970,668 |
| Total People Sold |
5 |
6 |
6 |
9 |
| Total Sell Transactions |
5 |
7 |
14 |
48 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-11-06 |
4 |
AS |
$11.25 |
$21,060 |
D/D |
(1,872) |
93,966 |
|
5% |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-10-08 |
4 |
AS |
$10.50 |
$238,497 |
D/D |
(22,714) |
95,838 |
|
-9% |
|
| Dreyfus Andrew |
Director |
– • – |
2020-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,600 |
112,003 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2020-09-08 |
4 |
AS |
$9.77 |
$77,672 |
D/D |
(7,950) |
123,107 |
|
11% |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-08-17 |
4 |
AS |
$10.14 |
$5,831 |
D/D |
(575) |
118,552 |
|
11% |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2020-08-17 |
4 |
AS |
$10.14 |
$6,986 |
D/D |
(689) |
235,776 |
|
11% |
|
| Dreyfus Andrew |
Director |
– • – |
2020-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,745 |
110,403 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2020-06-10 |
4 |
AS |
$10.06 |
$114,181 |
D/D |
(11,350) |
68,629 |
|
-8% |
|
| Currie Mark G |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
570,992 |
|
- |
|
| Mchugh Julie |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
131,057 |
|
- |
|
| Olanoff Lawrence S |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
79,979 |
|
- |
|
| Owens Edward P |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
203,954 |
|
- |
|
| Moukheibir Catherine |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
47,421 |
|
- |
|
| Duane Jon R |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
47,421 |
|
- |
|
| Kessler Marla L |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
47,421 |
|
- |
|
| Dreyfus Andrew |
Director |
– • – |
2020-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
21,720 |
108,658 |
|
- |
|
| Rickard Jason |
SVP, Chief Operating Officer |
• – – |
2020-05-11 |
4 |
AS |
$10.35 |
$5,279 |
D/D |
(510) |
234,580 |
|
-10% |
|
| Mallon Mark |
Chief Executive Officer |
• • – |
2020-05-11 |
4 |
AS |
$10.35 |
$240,182 |
D/D |
(23,206) |
501,280 |
|
-10% |
|
| Macdonald Kelly |
Chief Accounting Officer |
• – – |
2020-05-11 |
4 |
AS |
$10.35 |
$11,934 |
D/D |
(1,153) |
118,147 |
|
-10% |
|
| Kilroy Conor |
SVP, GC & Secretary |
• – – |
2020-05-11 |
4 |
AS |
$10.35 |
$7,411 |
D/D |
(716) |
128,921 |
|
-10% |
|
| Mccourt Thomas A |
President |
• – – |
2020-05-11 |
4 |
AS |
$10.35 |
$17,564 |
D/D |
(1,697) |
319,847 |
|
-10% |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt. |
• – – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,740 |
107,046 |
|
- |
|
| Kilroy Conor |
SVP, GC & Secretary |
• – – |
2020-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
22,814 |
129,637 |
|
- |
|
| Shetzline Michael |
CMO, SVP & Head of Drug Devt.O |
• – – |
2020-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
86,306 |
|
-1% |
|
| Rickard Jason |
SVP, Chief Operating OfficerOf |
• – – |
2020-04-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
235,090 |
|
-1% |
|
914 Records found
|
|
Page 9 of 37 |
|
|
0.18 (2.17%) 
